
Cipla Limited has informed the Exchange regarding a press release dated August 25, 2021, titled "Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars".
Filed with NSE · · 3 pages · English
Cipla and Kemwell Biopharma have announced a joint venture agreement for developing, manufacturing, and commercializing biosimilars. The joint venture aims to leverage the strengths of both companies to enhance product development and market entry in the respiratory biosimilars space. This partnership is expected to accelerate Cipla's global leadership in respiratory therapy and address unmet patient needs worldwide.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Cipla Limited has informed the Exchange regarding a press release dated August 25, 2021, titled "Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars".
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla